Jean Jacques Bienaime

CIK: 0001221590

Transaction Breakdown

Open Market Buys (P)22 (64.7%)

High conviction signal

Open Market Sales (S)2 (5.9%)

Position reduction

Option Exercises (M)1 (2.9%)

Derivative conversions

Awards (A)7 (20.6%)

Compensation grants

Other (G, F, J, C, D, …)2 (5.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

ASND

Ascendis Pharma A/S

Director

KROS

Keros Therapeutics, Inc.

Director

IMNM

Immunome Inc.

Director

INCY

INCYTE CORP

Director

Discretionary Trading P&L

Holdings

Transaction History (34 total)

KROS
Keros Therapeutics, Inc.
Aug 17, 2026
Purchase(P)
Direct
1K shares at avg. $10.27$10K
ASND
Ascendis Pharma A/S
Aug 14, 2026
Purchase(P)
Direct
900 shares at avg. $246.91$222K
ASND
Ascendis Pharma A/S
Aug 14, 2026
Purchase(P)
Direct
1.1K shares at avg. $245.85$270K
KROS
Keros Therapeutics, Inc.
Jul 15, 2026
Purchase(P)
Direct
1K shares at avg. $10.61$11K
KROS
Keros Therapeutics, Inc.
Jun 15, 2026
Purchase(P)
Direct
1K shares at avg. $10.19$10K
IMNM
Immunome Inc.
Jun 10, 2026
Award(A)
Director Stock Option (right to buy)
Direct
9.9K shares-
INCY
INCYTE CORP
Jun 8, 2026
Award(A)
Direct
1.6K shares-
IMNM
Immunome Inc.
Jun 5, 2026
Purchase(P)
Direct
1K shares at avg. $19.27$19K
IMNM
Immunome Inc.
Jun 5, 2026
Purchase(P)
Direct
6K shares at avg. $19.48$117K
IMNM
Immunome Inc.
Jun 5, 2026
Sale(S)
Direct
10K shares at avg. $19.41$194K
IMNM
Immunome Inc.
Jun 5, 2026
Sale(S)
Direct
500 shares at avg. $19.44$10K
IMNM
Immunome Inc.
Jun 5, 2026
Purchase(P)
Direct
3.5K shares at avg. $19.46$68K
KROS
Keros Therapeutics, Inc.
Jun 3, 2026
Award(A)
Direct
7.1K shares-
ASND
Ascendis Pharma A/S
May 29, 2026
Purchase(P)
Direct
200 shares at avg. $223.76$45K
ASND
Ascendis Pharma A/S
May 29, 2026
Purchase(P)
Direct
100 shares at avg. $223.50$22K
ASND
Ascendis Pharma A/S
May 29, 2026
Purchase(P)
Direct
200 shares at avg. $222.30$44K
INCY
INCYTE CORP
May 26, 2026
Tax Payment(F)
Direct
13.1K shares at avg. $97.10$1.3M
INCY
INCYTE CORP
May 26, 2026
Exercise(M)
Direct
15K shares at avg. $84.53$1.3M
ASND
Ascendis Pharma A/S
May 26, 2026
Purchase(P)
Direct
200 shares at avg. $239.37$48K
ASND
Ascendis Pharma A/S
May 26, 2026
Purchase(P)
Direct
200 shares at avg. $236.24$47K
KROS
Keros Therapeutics, Inc.
May 15, 2026
Purchase(P)
Direct
1K shares at avg. $10.58$11K
IMNM
Immunome Inc.
May 15, 2026
Purchase(P)
Direct
5K shares at avg. $20.70$104K
KROS
Keros Therapeutics, Inc.
Apr 15, 2026
Purchase(P)
Direct
1K shares at avg. $11.70$12K
ASND
Ascendis Pharma A/S
Apr 14, 2026
Award(A)
Warrants
Direct
9.2K shares-
ASND
Ascendis Pharma A/S
Apr 14, 2026
Disposition(D)
Warrants
Direct
9.2K shares-

		Type	Shares	Price		Ownership
Aug 17, 2026	KROS Keros Therapeutics, Inc.	Purchase(P)	1,000	$10.27	$10,270	Direct
Aug 14, 2026	ASND Ascendis Pharma A/S	Purchase(P)	900	$246.91	$222,219	Direct
Aug 14, 2026	ASND Ascendis Pharma A/S	Purchase(P)	1,100	$245.85	$270,435	Direct
Jul 15, 2026	KROS Keros Therapeutics, Inc.	Purchase(P)	1,000	$10.61	$10,610	Direct
Jun 15, 2026	KROS Keros Therapeutics, Inc.	Purchase(P)	1,000	$10.19	$10,190	Direct
Jun 10, 2026	IMNM Immunome Inc.	Award(A) Director Stock Option (right to buy)	9,897	-	-	Direct
Jun 8, 2026	INCY INCYTE CORP	Award(A)	1,642	-	$0	Direct
Jun 5, 2026	IMNM Immunome Inc.	Purchase(P)	1,000	$19.27	$19,270	Direct
Jun 5, 2026	IMNM Immunome Inc.	Purchase(P)	6,000	$19.48	$116,880	Direct
Jun 5, 2026	IMNM Immunome Inc.	Sale(S)	10,000	$19.41	$194,100	Direct
Jun 5, 2026	IMNM Immunome Inc.	Sale(S)	500	$19.44	$9,720	Direct
Jun 5, 2026	IMNM Immunome Inc.	Purchase(P)	3,500	$19.46	$68,110	Direct
Jun 3, 2026	KROS Keros Therapeutics, Inc.	Award(A)	7,142	-	$0	Direct
May 29, 2026	ASND Ascendis Pharma A/S	Purchase(P)	200	$223.76	$44,752	Direct
May 29, 2026	ASND Ascendis Pharma A/S	Purchase(P)	100	$223.50	$22,350	Direct
May 29, 2026	ASND Ascendis Pharma A/S	Purchase(P)	200	$222.30	$44,460	Direct
May 26, 2026	INCY INCYTE CORP	Tax Payment(F)	13,059	$97.10	$1,268,029	Direct
May 26, 2026	INCY INCYTE CORP	Exercise(M)	15,000	$84.53	$1,267,950	Direct
May 26, 2026	ASND Ascendis Pharma A/S	Purchase(P)	200	$239.37	$47,874	Direct
May 26, 2026	ASND Ascendis Pharma A/S	Purchase(P)	200	$236.24	$47,247	Direct
May 15, 2026	KROS Keros Therapeutics, Inc.	Purchase(P)	1,000	$10.58	$10,580	Direct
May 15, 2026	IMNM Immunome Inc.	Purchase(P)	5,000	$20.70	$103,500	Direct
Apr 15, 2026	KROS Keros Therapeutics, Inc.	Purchase(P)	1,000	$11.70	$11,700	Direct
Apr 14, 2026	ASND Ascendis Pharma A/S	Award(A) Warrants	9,160	-	-	Direct
Apr 14, 2026	ASND Ascendis Pharma A/S	Disposition(D) Warrants	9,160	-	-	Direct

1-25 of 34 transactions

About BIENAIME JEAN JACQUES

BIENAIME JEAN JACQUES (SEC CIK 0001221590) files insider reports with the SEC as Director of Ascendis Pharma A/S (ASND), Director of Keros Therapeutics, Inc. (KROS) and Director of Immunome Inc. (IMNM). Signal8 also holds filings tied to 1 other company.

Signal8 holds 24 ownership filings by BIENAIME JEAN JACQUES (1 Form 3, 23 Form 4), filed between Mar 25, 2025 and Sep 28, 2026. Those filings report 34 transactions, from Mar 24, 2025 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BIENAIME JEAN JACQUES's filings is in HELLERUP.

Recent filings by BIENAIME JEAN JACQUES

Aug 17, 2026: Open-market purchase of KROS shares (Form 4, code P).
Aug 14, 2026: Open-market purchases of ASND shares (2 lines, Form 4, code P).
Jul 15, 2026: Open-market purchase of KROS shares (Form 4, code P).
Jun 15, 2026: Open-market purchase of KROS shares (Form 4, code P).
Jun 10, 2026: Grant or award of IMNM derivative securities (Form 4, code A).

Other insiders filing for Ascendis Pharma A/S (ASND)

Bodenhoff Mads, SVP & PAO
HOLTUG LARS, Director
SMITH SCOTT THOMAS, EVP & Chief Financial Officer
JENSEN FLEMMING STEEN
Fairey William, Director
IMANI SIHAM, Director

How to read Form 4 transaction codes